| Identification | Back Directory | [Name]
2,6-Piperidinedione, 3-[4-(4-methoxy-3-thienyl)-1H-1,2,3-triazol-1-yl]- | [CAS]
2367619-87-0 | [Synonyms]
FPFT-2216
2,6-Piperidinedione, 3-[4-(4-methoxy-3-thienyl)-1H-1,2,3-triazol-1-yl]- | [Molecular Formula]
C12H12N4O3S | [MOL File]
2367619-87-0.mol | [Molecular Weight]
292.31 |
| Chemical Properties | Back Directory | [density ]
1.62±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
10.40±0.40(Predicted) | [color ]
Light yellow to light brown |
| Hazard Information | Back Directory | [Biological Activity]
FPFT-2216, a "molecular glue" compound, degrades phosphodiesterase 6D (PDE6D), zinc finger transcription factors Ikaros (IKZF1), Aiolos (IKZF3), and casein kinase 1α (CK1α). FPFT-2216 can be used for the research of cancer and inflammatory disease[1][2].
FPFT-2216 (1 μM; 5 hours) is able to degrade PDE6D, in addition to its known targets IKZF1, IKZF3, and CK1α in MOLT4 cells[1].FPFT-2216 (1 μM; 0 h, 2 h, 4 h, 6 h, 16 h, 24 h) shows complete degradation of PDE6D within 2 h, and the degradation of PDE6D persists for at least 24 h in MOLT4 cells[1].FPFT-2216 (0 nM, 1.6 nM, 8 nM, 40 nM, 200 nM, 1 μM; 4 h) exhibits over 50% degradation of PDE6D at a dose of 8 nM, while maximum degradation of PDE6D along with IKZF1, IKZF3, and CK1α at a dose of 200 nM in MOLT4 cells[1].FPFT-2216 does not impede the growth of KRASG12C-dependent MIA PaCa-2 cells[1].FPFT-2216 (10, 20, 40 μM; 14 or 24 h) highly up-regulates the production of IL-2 although it is less potent than that of Pomalidomide in Naive CD4+ T cells[2].FPFT-2216 (10 μM; 14 or 24 h) degrades IKZF1 and CK-1α among ubiquitin-proteasomal degradative substrates of immunomodulatory drugs (IMiDs) in Naive CD4+ T cells[2].
FPFT-2216 (30 mg/kg; p.o. or i.p.) induces significant degradation of CK-1α, and IKZF1 in CRBNI391V mice[2]. | [storage]
Store at -20°C | [References]
[1]. Teng M, et al. Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216. J Med Chem. 2022 Jan 13;65(1):747-756. [2]. Gemechu Y, et al. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs. Proc Natl Acad Sci U S A. 2018;115(46):11802-11807. |
|
|